anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Early hypoperfusion changes exist in patients with aneurysmal subarachnoid hemorrhage (aSAH). We aimed to investigate a readily obtainable quantitative computed tomography perfusion (CTP) parameter that could assist in quickly identifying patients at risk of delayed cerebral ischemia (DCI) and poor 90-day functional outcomes on admission.
METHODS: We prospectively collected data between 2021.04 and 2022.12. Preoperative CTP data were post-processed using RAPID software. The cortical blood flow insufficiency (CBFI) was defined as Time-to-maximum > 4.0 s. Patients were categorized into four groups according to CBFI volume distribution. To minimize differences among the groups, we employed stabilized inverse probability of treatment weighting (sIPTW). The primary outcome was DCI and poor 90-day functional outcomes (modified Rankin Scale, 3-6) was the secondary outcome. Multivariable Cox or Logistic analysis were performed to estimate the association between CBFI volume and the study outcomes, both before and after sIPTW.
RESULTS: At baseline, the mean (SD) age of the 493 participants was 55.0 (11.8) years, and 299 (60.6%) were female. One hundred and seven participants with DCI and eighty-six participants with poor 90-day functional outcomes were identified. After sIPTW, CBFI volume demonstrated a significant association with DCI (Cox regression: Group 4 versus Group 1, HR 3.69, 95% CI 1.84-7.01) and poor 90-day functional outcomes (Logistic regression: Group 4 versus Group 1, OR 4.61, 95% CI 2.01-12.50).
CONCLUSION: In this study, an elevated preoperative CBFI volume was associated with adverse outcomes in aSAH patients. More well-designed studies are needed to confirm this association.
PROBLEM TO BE SOLVED: To provide a foaming aerosol product including a propellant containing carbon dioxide and having excellent foamability and fine foam quality.SOLUTION: In a foaming aerosol product, a pressure-resistant container is filled with [A] a stock solution containing an anionic surfactant and [B] a propellant. The propellant [B] contains an isopentane, a liquefied petroleum gas and carbon dioxide. The mass ratio of the total amount of the isopentane and the liquefied petroleum gas to the amount of the stock solution [A] is at least 4/96 to at most 10/90. The foaming aerosol product is preferrably used as a shampoo. Also, the filling amount of the liquefied petroleum gas is preferably greater than the filling amount of the isopentane. Further, the anionic surfactant preferably contains a polyoxyethylene lauryl ether acetate salt and a polyoxyethylene sulfosuccinic acid lauryl salt.
OBJECTIVE: Patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) after primary local therapy have low response rates with cetuximab, systemic chemotherapy or check point inhibitor therapy. Novel combination therapies with the potential to improve outcomes for patients with HNSCC is an area of high unmet need.
METHODS: This is a phase II single-arm clinical trial of locally advanced or metastatic HNSCC patients treated with a combination of soluble EphB4-human serum albumin (sEphB4-HSA) fusion protein and pembrolizumab after platinum-based chemotherapy with up to 2 prior lines of treatment. The primary endpoints were safety and tolerability and the primary efficacy endpoint was overall response rate (ORR). Secondary endpoints included progression free survival (PFS) and overall survival (OS). HPV status and EphrinB2 expression were evaluated for outcome.
RESULTS: Twenty-five patients were enrolled. Median follow up was 40.4 months (range 9.8 - 40.4). There were 6 responders (ORR 24%). There were 5 responders in the 11 HPV-negative and EphrinB2 positive patients, (ORR 45%) with 2 of these patients achieving a complete response (CR). The median PFS in HPV-negative/EphrinB2 positive patients was 3.2 months (95% CI 1.1, 7.3). Median OS in HPV-negative/EphrinB2 positive patients was 10.9 months (95% CI 2.0, 13.7). Hypertension, transaminitis and fatigue were the most common toxicities.
DISCUSSION: The combination of sEphB4-HSA and pembrolizumab has a favorable toxicity profile and favorable activity particularly among HPV-negative EphrinB2 positive patients with HNSCC.
The invention belongs to the technical field of microorganisms, and discloses a high-temperature-resistant virulent staphylococcus aureus phage, a separation method and application thereof. The phage is named RKP-SR-22003 and is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) at the year 2023, and the preservation address is: the preservation number of the Qingyang area North Star Xili No. 1 and 3 of Beijing is CGMCC No.45444. The invention separates a strain of avian staphylococcus aureus, and takes the staphylococcus aureus as a host to separate and obtain the phage. The staphylococcus aureus phage can maintain higher stability in the passage process. The phage has strong cracking effect on the avian staphylococcus aureus in the culture environment, and provides a good phage source for the industrial production of phage for the prevention and the control of the avian staphylococcus aureus in the culture environment.
742,194. Rivets; hinges. ROLLS-ROYCE, Ltd. March 26, 1954 [April 10, 1953], No. 9883/53. Classes 65 (2) and 89 (1). [Also in Group XXVI] In a pivotal connection between a blade and a compressor or turbine rotor, the blade or rotor has at least two lugs each of which extends between a pair of lugs on the other part, and the pivot-pin comprises a number of axiallyaligned elements each of which engages bores in a lug and the lugs on each side of the latter. In Fig. 3 the pivot-pin comprises elements 16, 17, element 17 being formed with a head 18 and with a stem 19 having an enlarged head 20. The element 16 has an inwardly-directed flange 21 with an aperture 22, 23 shaped so that the head 20 may be entered through the part 23 of the aperture and when the two elements are axially aligned, the stem 19 engages the part 22 and relative endwise movement of the two elements is prevented or limited to a small extent. In a further embodiment, Fig. 6, two elements 25 are hollow and are connected by a hollow rivet 27 engaging countersunk portions at the ends of the two elements. The rivet 27 is screwthreaded to receive a plug 31 used for balancing purposes.
A patient case may be evaluated whenever new information is received or as scheduled. Evaluation may include resolving a Diagnosis-Related Group (DRG) code and determining a CDI scoring approach based at least in part on a result from the resolving. Resolving a DRG code may include determining whether a DRG code is associated with the patient case. If no DRG code is found, the system may search for an International Classification of Diseases code or ask a user to select or assign a DRG code. Using the determined CDI scoring approach, a first score may be generated and adjusted by at least one of length of stay, documentation accuracy, payer, patient location, documentation novelty, review timing, case size, or documentation sufficiency. The adjusted score may be normalized and presented to a CDI specialist, perhaps with multiple CDI scores in a sorted order.
Early intervention. Quasiexperimental study. Inclusion of 150 first times families in intervention and matched with 150 families from control group.
FIELD: experimental medicine, toxicology. SUBSTANCE: composition has the total ginseng root glycoside extract, aralia root extract and licorice root extract. Other variant of composition has the total glycoside extract of ginseng culture tissue and ethanol extracts of aralia and licorice root. Compositions show the expressed capability to recover central nervous system disorders after alcohol excess doses effect, positive organoleptic properties and can be used as curative-prophylaxis food addition. EFFECT: enhanced effectiveness of composition, absence of toxicity, safety. 1 cl, 3 tbl
The subjects will perform clinical, psychological and neuropsychological assessment. the subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
The high prevalence of obesity and its medical consequences make it one of the most important public health issues in the United States today. Few interventions have been consistently successful at reducing obesity. This trial will test an intervention program that lasts 22 weeks, with 16 evening sessions and one weekend day. Participants will be randomized to one of two arms. Both arms will receive diet and exercise intervention elements. The study aims for gradual weight loss, with a calorie target that will maintain ideal body weight, rather than a more calorie restricted diet. The exercise component is based around increasing walking. The arms will compare methods for producing long-lasting behavior change.
Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every 4 weeks for a total of 6 weeks. To ensure blinding, each subject will receive placebo every other week.
Alopecia associated with lupus erythematosus is broadly classified into reversible nonscarring alopecia seen in the acute phase, such as worsening of systemic lupus erythematosus (SLE) and cicatricial alopecia seen in chronic cutaneous lupus erythematosus represented by discoid lupus erythematosus (DLE). In DLE-induced alopecia, early therapeutic intervention before developing scarring alopecia is important, but the condition is often resistant to conventional treatment. Anifrolumab (ANI), a novel therapeutic agent for SLE that inhibits Type I interferon activity, has been shown to be effective against acute skin lesions, including alopecia, in patients with SLE. However, there are very few reports on the effect of ANI on alopecia due to DLE. We report on a 27-year-old Japanese woman with SLE whose alopecia due to chronic DLE was refractory to topical therapy and systemic therapy with oral glucocorticoid, multiple immunosuppressants, and belimumab for ∼8 years after onset and whose alopecia improved with ANI. ANI can be considered to be an effective treatment option in lupus patients presenting with alopecia due to DLE, even in the chronic refractory stage.
Participants receive defined green tea catechin extract PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo ultrasound, CT, or MRI at screening and on study, undergo collection of blood samples on study, and may undergo biopsy at screening and on study.
BACKGROUND: Vertical orbital dystopia (VOD) results in significant facial asymmetry, psychological distress, and poor quality of life in affected patients. The traditional approach (TA) for surgical correction has entailed a standard frontal craniotomy along with circumferential orbital osteotomy, vertical translocation of the orbit, and bone grafting to the lower maxilla. Caution has been expressed regarding its invasive transcranial nature. In this report, the authors describe the limited approach (LA) for simplified surgical correction of VOD, which obviates the need for a standard frontal craniotomy.
METHODS: A 45-year retrospective review was conducted of all patients who underwent surgical correction of VOD, as performed by a single surgeon. Demographic details, procedural characteristics, and complications were compared between patients who underwent correction by the TA and those who underwent correction by the LA. Complications were defined as cerebrospinal fluid leak, infection of the frontal bone, permanent diplopia, permanent ptosis, sudden-onset vision loss, persistent asymmetry, and surgical revision.
RESULTS: Forty patients met inclusion criteria for correction of true VOD, of which 18 underwent the TA and 22 underwent the LA. Mean length of hospital stay was 5.3 ± 2.3 days and 4.0 ± 1.5 days for the TA and LA cohorts, respectively. Mean follow-up time was 4.9 ± 7.5 years for the TA cohort and 2.6 ± 3.3 years for the LA cohort. The only reported complications were persistent asymmetry in 2 patients in the TA cohort, with 1 patient requiring surgical revision because of undercorrection, whereas the LA cohort exhibited no postoperative asymmetry or need for surgical revision.
CONCLUSIONS: Both the TA and the LA are effective for surgical correction of VOD. The limited craniotomy of the LA reduces exposure of intracranial structures and adequately achieves postoperative symmetry.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
This web-based database was launched on June 13, 2015 and consists of tertiary or secondary hospitals with special interest and expertise on managing genetic/metabolic liver diseases patients across mainland China. The main inclusion criteria for this registration are patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other genetic/metabolic liver diseases. At the first time of data entry, demographics, medical history, biochemistry and hematology results, radiology reports, diagnosis and treatment information were recorded. Patients' whole blood and serum were collected for molecular genetic testing and future researches. Then the registered patients will receive standard of care and be followed-up every 6 to 12 months. On each visit, biochemical, radiological reports, as well as clinical progress were recorded.
A culture method for determining the effect of a biological agent on multipotent neural stem cell progeny is provided. In the presence of growth factors, multipotent neural stem cells are induced to proliferate in culture. The multipotent neural stem cells may be obtained from normal neural tissue or from a donor afflicted with a disease such as Alzheimer's Disease, Parkinson's Disease or Down's Syndrome. At various stages in the differentiation process of the multipotent neural stem cell progeny, the effects of a biological agent, such as a virus, protein, peptide, amino acid, lipid, carbohydrate, nucleic acid or a drug or pro-drug on cell activity are determined. Additionally, a method of screening the effects of biological agents on a clonal population of neural cells is provided. The technology provides an efficient method for the generation of large numbers of pre- and post-natal neural cells under controlled, defined conditions. The disclosed cultures provide an optimal source of normal and diseased neural cells at various developmental stages, which can be screened for potential side effects in addition to testing the action and efficacy of different biological agents.
The investigators will implement a Targeted Educational Campaign (TEC) within 3 jails. The TEC is designed to lead to referrals of detainees (previously not detected as having potential mental health concerns) to Correctional Health Services (CHS) by Correction Officers.
To provide conjugates of cartilage-homing peptides.SOLUTION: Disclosed are compositions, such as pharmaceutical compositions, and uses thereof for peptide-drug conjugates. In various aspects, the present disclosure provides a conjugate. Here, the conjugate comprises an anti-arthritic agent, a cystine-dense peptide, and a linker. Upon administration to a subject, the cystine-dense peptide homes, targets, migrates to, accumulates in, binds to, is retained by, or is directed to a cartilage of the subject. The linker comprises a cyclic carboxylic acid, a cyclic dicarboxylic acid, an aromatic dicarboxylic acid, or an amino acid. Here, the linker conjugates the anti -arthritic agent and the cystine-dense peptide via an ester bond, a carbamate bond, a carbonate bond, or an amide bond.SELECTED DRAWING: None
Patients receive carboplatin and paclitaxel as in arm I. Patients also receive cixutumumab IV over 1 hour on days 1, 15, and 29. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cixutumumab alone on days 1, 15, and 29. Treatment with cixutumumab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
PURPOSE:To produce the titled composition having excellent discoloration stability, and useful as a colorant or a vitamin A source in the form of vitamin A precursor, by dissolving a carotenoid in vitamin E under heating. CONSTITUTION:A carotenoid (e.g. alpha-carotene) is dissolved in vitamin E (e.g. alpha- tocopherol) under heating. If necessary, a solution or dispersion of an antioxidant, a surface active agent, a density modifier, etc. is added to the above mixture, and the product is emulsified or pulverized with an emulsifier such as a homomixer. The produced oil phase of vitamin E containing the carotenoid can be supplied as it is according to the use such as a source of vitamin A or vitamin E, etc., or can be encapsulated to microcapsules.
The aim of this trial is to study the effects of simulation education on the action of the group managing patient's airway in the intensive care unit (ICU). Before simulations investigators will video-record 20 real-world intubations. Consequently will be run simulations to whole staff of the ICU. After the education further 20 real-world intubations will be recorded. Also simulations are recorded. From the videos investigators assess technical and non-technical skills of the group before and after simulation education, correlations between groups and influence of the education on action of the group. On the first part of the study, hypothesis is that group's good non-technical skills improve also technical skills. On the second part of the study hypothesis is that performing well in simulation correlates with performing well in real-world situation and teams with less experience the correlation is stronger.
<P>PROBLEM TO BE SOLVED: To provide an apoptosis-inducing substance which contains a carotenoid pigment-containing extract originated from carotenoid-containing potato as an active ingredient, has greatly high safety, is more inexpensive than conventional anticancer agents, does not produce side effects, and can continuously be taken.  <P>SOLUTION: This apoptosis-inducing substance comprises a carotenoid pigment-containing extract extracted from a potato kind which is an ancestral potato kind for ordinary culture potato kinds, such as Solanum tuberosum ssp. tuberosam L. or Solanum phureja Juz. et Buk, a different culture potato kind, or a mated breeding kind based on them, improved in agronomic characters such as pigment concentration, disease resistance, yield or the like, and containing a carotenoid pigment in the flesh portion, has a yellow color tone of raw potato flesh portion in comparison with the Solanum tuberosum ssp. tuberosam L., and contains a carotenoid-based yellow pigment: zeaxanthin which is a main ingredient for forming the color tone of the flesh portion of the potato, in a concentration of ≥3 μg/g and has b<SP>*</SP>of ≥30 in L<SP>*</SP>, a<SP>*</SP>and b<SP>*</SP>color system and measured by a colorimeter, as a main ingredient for forming the color tone of the flesh portion.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Placental growth factor (PlGF)-2 induces angio- and arteriogenesis in rodents but its therapeutic potential in a clinically representative post-infarction left ventricular (LV) dysfunction model remains unclear. We, therefore, investigated the safety and efficacy of recombinant human (rh)PlGF-2 in the infarcted porcine heart in a randomized, placebo-controlled blinded study. We induced myocardial infarction (MI) in pigs using 75 min mid-LAD balloon occlusion followed by reperfusion. After 4 w, we randomized pigs with marked LV dysfunction (LVEF < 40%) to receive continuous intravenous infusion of 5, 15, 45 µg/kg/day rhPlGF-2 or PBS (CON) for 2 w using osmotic pumps. We evaluated the treatment effect at 8 w using comprehensive MRI and immunohistochemistry and measured myocardial PlGF-2 receptor transcript levels. At 4 w after MI, infarct size was 16-18 ± 4% of LV mass, resulting in significantly impaired systolic function (LVEF 34 ± 4%). In the pilot study (3 pigs/dose), PIGF administration showed sustained dose-dependent increases in plasma concentrations for 14 days without systemic toxicity and was associated with favorable post-infarct remodeling. In the second phase (n = 42), we detected no significant differences at 8 w between CON and PlGF-treated pigs in infarct size, capillary or arteriolar density, global LV function and regional myocardial blood flow at rest or during stress. Molecular analysis showed significant downregulation of the main PlGF-2 receptor, pVEGFR-1, in dysfunctional myocardium. Chronic rhPIGF-2 infusion was safe but failed to induce therapeutic neovascularization and improve global cardiac function after myocardial infarction in pigs. Our data emphasize the critical need for properly designed trials in representative large animal models before translating presumed promising therapies to patients.
Cerebral ischaemia-reperfusion (CIR) injury occurs in stroke patients after the restoration of cerebral perfusion. Sinigrin, a phytochemical found in cruciferous vegetables, exhibits strong antioxidant activity. This study investigated the role of sinigrin in oxidative stress using a CIR injury model. The effects of sinigrin were studied in middle cerebral artery occlusion (MCAO) rats and oxygen-glucose deprivation/reoxygenation (OGD/R)-injured SH-SY5Y cells. Sinigrin treatment improved brain injury and neurological deficits induced by MCAO surgery in rats. Sinigrin inhibited apoptosis in brain tissues and SH-SY5Y cells following OGD/R induction. Additionally, sinigrin elevated the levels of superoxide dismutase (SOD), glutathione (GSH) and glutathione peroxidase (GSH-Px) while reducing malondialdehyde (MDA) levels. Furthermore, sinigrin inhibited the toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88) signalling pathway. The anti-apoptotic and antioxidant activities of sinigrin in OGD/R-injured SH-SY5Y cells were reversed by TLR4 overexpression. In conclusion, sinigrin inhibits oxidative stress in CIR injury by suppressing the TLR4/MyD88 signalling pathway.
A method increases production of ketones derived from oral consumption of medium chain triglycerides (MCT) by an individual. The method includes orally administering to the individual a composition containing the MCTs and then subsequently orally administering to the individual a meal at least about ten minutes after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The ketone production is increased relative to ketone production from oral administration of the MCTs and the meal at approximately the same time. The meal can be breakfast. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.
PURPOSE: Provided are compositions which are useful for providing protection to the skin of humans from the harmful effects of ultraviolet radiation. In particular compositions having improved chemical, physical, and photostability are provided. CONSTITUTION: Provided are photoprotective compositions having enhanced stability that are useful for protecting human skin from the harmful effects of UV radiation, comprising: (a) from about 0.1% to about 10% of a dibenzoylmethane sunscreen compound, (b) from about 0.1% to about 20% of a surface-treated zinc oxide having a mean particle size diameter from about 0.01 microns to about 100 microns, and (c) a carrier suitable for application to human skin. All percentages and ratios used herein are by weight of the total composition. All measurements made are at 25°C., unless otherwise designated. All weight percentages, unless otherwise indicated, are on an actives weight basis. The composition can comprise, consist or, or consist essentially or, the essential as well as optional ingredients and components described herein.